Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

2.8K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of an epitope-based vaccine from <i>mycoplasma genitalium</i> adhesion protein: addressing antibiotic resistance through immune-informatics.

Toxicology research·2025
Same author

Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.

JAMA oncology·2023
Same author

Immune checkpoint inhibitors in liver transplant: a case series.

Journal of gastrointestinal oncology·2023
Same author

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.

Nature medicine·2023
Same author

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML.

Blood advances·2022
Same author

Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.

Blood cancer discovery·2022

Related Experiment Video

Updated: May 1, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.2K

Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.

Abhimanyu Ghose1, Ria Kundu1, Tahir Latif1

  • 1Division of Hematology/Oncology, University of Cincinnati, United States.

Critical Reviews in Oncology/Hematology
|April 5, 2014
PubMed
Summary

Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is rare but serious. CNS prophylaxis is crucial, especially in the rituximab era, to identify high-risk patients and improve outcomes.

Keywords:
CNSDiffuse large B cellLymphomaProphylaxis

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Related Experiment Videos

Last Updated: May 1, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.2K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Area of Science:

  • Hematology
  • Oncology
  • Neurology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) survival has improved with rituximab.
  • Central nervous system (CNS) involvement in DLBCL presents a poor prognosis.
  • CNS relapse is an uncommon but critical complication.

Purpose of the Study:

  • To review the incidence of CNS relapse in DLBCL.
  • To evaluate the role of CNS prophylaxis in the pre- and post-rituximab eras.
  • To identify high-risk DLBCL patients who benefit from CNS prophylaxis.

Main Methods:

  • Extensive literature review of DLBCL and CNS relapse.
  • Analysis of CNS prophylaxis strategies and their efficacy.
  • Development of a treatment algorithm for CNS prophylaxis.

Main Results:

  • Rituximab has improved overall survival in DLBCL.
  • CNS relapse in DLBCL carries a median survival under 6 months.
  • Limited randomized trials exist for CNS prophylactic strategies.

Conclusions:

  • Identifying patients who benefit most from CNS prophylaxis is essential due to inherent toxicities.
  • A treatment algorithm is proposed to guide CNS prophylaxis in DLBCL management.
  • Further research is needed to optimize CNS prophylaxis in DLBCL.